康王品牌怎么样 申请店铺

我要投票 康王在洗发水行业中的票数:1115 更新时间:2026-01-28
康王是哪个国家的品牌?「康王」是 拜耳医药保健有限公司 旗下著名品牌。该品牌发源于云南省昆明市,由创始人沃纳·保在1996年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力康王品牌出海!将品牌入驻外推网,定制康王品牌推广信息,可以显著提高康王产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

康王怎么样

始于1996年,滇虹药业旗下发用洗剂品牌,2015年归入拜耳集团旗下,专注于专业药物去屑洗剂研究的OTC药物去屑品牌


康王于1996年上市,始终专业药物去屑洗剂的研究,是国内“药物去屑”的影响力品牌。

滇虹药业集团前身为中美合资昆明滇虹药业有限公司,系由滇虹天然药物厂与美国大东企业于1997年合资设立,承继1993年注册成立的滇虹天然药物厂的全部业务,设立至今始终由中方控股。2012年,昆明滇虹药业有限公司改制变更为滇虹药业集团股份有限公司。

滇虹药业集团是一家研发导向型、集研发、生产和营销为一体的现代化制药企业集团。滇虹药业现有员工3000余名,营销网络覆盖全国乃至东南亚国家及非洲地区。

伴随企业社会知名度和美誉度的不断提升,公司正式确立了植根于品牌的“以消费者大健康产业为主体,以拓展医药及国际市场为两翼”的“一体两翼”消费者大健康产业发展战略。在这一战略指引下,滇虹药业积极推动中国负责任的自我保健及自我药疗事业进程,推动设立国际自我保健日。同时展开产业整合,打造中药标准化平台,集中优势资源将民族品牌做强做大。

依托高质量的产品优势和良好的企业文化积淀,滇虹药业气势如虹,开疆拓土,在大健康产业领域以良好的发展态势傲视同侪。 秉持“以人为本、艰苦奋斗、科技兴药”的企业理念,怀着“关注健康,造福人类”的企业追求,滇虹愿与社会各界人士携手,共襄医药产业美好未来。

2014年11月3日,拜耳集团已完成对滇虹药业集团公司所有股份的收购。滇虹药业是一家中国云南昆明的民营制药公司,主要生产皮肤科非处方药物(OTC)和用以治疗各类妇科疾病的传统中草药产品。拜耳公司支付的收购价格为36亿元人民币(约合4.6亿欧元)。


Started in 1996, the hair lotion brand of Dianhong Pharmaceutical Co., Ltd. was incorporated into Bayer Group in 2015. Kangwang, an OTC pharmaceutical dandruff remover brand focusing on the research of professional pharmaceutical dandruff removers, went on the market in 1996 and has always been specialized in the research of pharmaceutical dandruff removers. It is the influential brand of "pharmaceutical dandruff removers" in China. Yunnan Hong Pharmaceutical Group, formerly known as Sino US joint venture Kunming Yunnan Hong Pharmaceutical Co., Ltd., is a joint venture established by Yunnan Hong Natural Pharmaceutical Co., Ltd. and Dadong enterprise of the United States in 1997. It inherits all businesses of Yunnan Hong Natural Pharmaceutical Co., Ltd. registered in 1993 and has been controlled by China ever since its establishment. In 2012, the restructuring of Kunming Dianhong Pharmaceutical Co., Ltd. was changed to Dianhong Pharmaceutical Group Co., Ltd. Dianhong Pharmaceutical Group is a R & D-oriented, research and development, production and marketing as one of the modern pharmaceutical enterprise groups. Dianhong pharmaceutical has more than 3000 employees, and its marketing network covers the whole country, even Southeast Asian countries and Africa. With the continuous improvement of corporate social popularity and reputation, the company has officially established the "one body and two wings" development strategy of consumer health industry, which is rooted in the brand and takes the consumer health industry as the main body and the expansion of medicine and international market as the two wings. Under the guidance of this strategy, Dianhong pharmaceutical actively promotes China's responsible self-care and self medication career, and promotes the establishment of the international self care day. At the same time, we will carry out industrial integration, build a platform for standardization of traditional Chinese medicine, and focus on advantageous resources to strengthen and expand national brands. Relying on the advantages of high-quality products and good corporate culture accumulation, Dianhong pharmaceutical industry is in a great momentum, expanding its territory and dominating its peers in the field of big health industry with a good development momentum. Adhering to the enterprise concept of "people-oriented, hard work, science and technology to promote medicine" and the enterprise pursuit of "focusing on health and benefiting mankind", Dianhong is willing to work with people from all walks of life to share the bright future of medicine industry. On November 3, 2014, Bayer Group completed the acquisition of all shares of Dianhong Pharmaceutical Group. Dianhong Pharmaceutical Co., Ltd. is a private pharmaceutical company in Kunming, Yunnan, China. It mainly produces OTC and traditional Chinese herbal medicine products for treating various gynecological diseases. Bayer paid 3.6 billion yuan (460 million euros) for the acquisition.

本文链接: https://brand.waitui.com/8dbbe51ba.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

苹果据悉今年9月只上iPhone18 Pro系列和首款阔折叠Fold

市场消息称,苹果iPhone 18预计明年Q1推出,9月只上iPhone18 Pro系列和首款阔折叠iPhone Fold,基本都是万元机档位。苹果今年秋季发布的所有新款iPhone都配备12GB内存,涵盖iPhone 18 Pro、iPhone 18 Pro Max以及iPhone Fold(折叠屏 iPhone),与 iPhone 17 Pro系列所采用的12GB内存保持一致。(财联社)

2小时前

美股大型科技股盘前多数上涨,英特尔涨超5%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,英特尔涨超5%,英伟达涨超2%,谷歌涨0.44%,亚马逊涨0.22%,微软涨0.31%,特斯拉涨0.19%,Meta跌0.28%,苹果跌0.19%。

2小时前

热门中概股美股盘前普涨,哔哩哔哩涨超4%

36氪获悉,热门中概股美股盘前普涨,截至发稿,哔哩哔哩涨超4%,蔚来、理想汽车涨超3%,阿里巴巴、网易、小鹏汽车涨超2%,百度涨超1%,拼多多涨0.61%,京东涨0.54%。

2小时前

星巴克:第一季度美国同店销售额增长4% 高于市场预期

星巴克第一季度美国同店销售额增长4%,预估为增长1.88%。星巴克预计全年同店销售至少增长3%,市场预估增长2.83%;预计全年调整后每股收益2.15美元至2.40美元。(财联社)

2小时前

*ST铖昌:预计2025年净利润9500万元-1.24亿元,公司股票存在可能被终止上市的风险

36氪获悉,*ST铖昌公告,*ST铖昌预计2025年归属于上市公司股东的净利润为9500万元–12400万元,上年同期为亏损3111.79万元,同比扭亏为盈。公司股票因2024年度经审计净利润为负值且扣除后营业收入低于3亿元,自2025年4月24日起被实施退市风险警示。若公司2025年度出现《深圳证券交易所股票上市规则》第9.3.12条规定的相关情形,公司股票将面临被终止上市的风险。公司已披露股票可能被终止上市的风险提示公告,并计划更换会计师事务所以推进2025年度审计工作。

2小时前

本页详细列出关于康王的品牌信息,含品牌所属公司介绍,康王所处行业的品牌地位及优势。
咨询